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S U M M A R Y
Objectives: To determine (1) gender-related differences in antiretroviral therapy (ART) outcomes, and (2)
gender-speciﬁc characteristics associated with attrition.
Methods: This was a retrospective patient record review of 3919 HIV-infected patients aged 15 years
who initiated ART between 2007 and 2009 in 40 randomly selected ART facilities countrywide.
Results: Compared to females, males had more documented active tuberculosis (12% vs. 9%; p < 0.02)
and a lower median CD4 cell count (117 cells/ml vs. 143 cells/ml; p < 0.001) at ART initiation.
Males had a higher risk of attrition (adjusted hazard ratio (AHR) 1.28, 95% conﬁdence interval (CI)
1.10–1.49) and mortality (AHR 1.56, 95% CI 1.10–2.20). Factors associated with attrition for both
sexes were lower baseline weight (<45 kg and 45–60 kg vs. >60 kg), initiating ART at an urban
health facility, and care at central/provincial or district/mission hospitals vs. primary healthcare
facilities.
Conclusions: Our ﬁndings show that males presented late for ART initiation compared to females. Similar
to other studies, males had higher patient attrition and mortality compared to females and this may be
attributed in part to late presentation for HIV treatment and care. These observations highlight the need
to encourage early HIV testing and enrolment into HIV treatment and care, and eventually patient
retention on ART, particularly amongst men.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
With only 12% of the world’s population, Sub-Saharan Africa
has 68% of the world’s burden of HIV/AIDS cases.1 Zimbabwe, a
country in southern Africa, is also badly affected by the HIV/AIDS
epidemic, with recent statistics showing an HIV prevalence of
15% in the 15–49 years age group according to the 2010–2011
Zimbabwe Demographic and Health Survey.2
Since the national antiretroviral treatment (ART) programme
was initiated in 2004, there has been a continuous increase in the
cohort of HIV-infected individuals accessing this life-saving* Corresponding author. Tel.: +263 4 2933495.
E-mail address: ktakarinda@theunion.org (K.C. Takarinda).
http://dx.doi.org/10.1016/j.ijid.2014.11.009
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).intervention in Zimbabwe. The number of health facilities offering
ART services increased from 7 in 2004 to 960 by December 2012,3
and those receiving ART increased from 24 500 people in 2005 to
531 136 by the end of 2012.3 In terms of adult ART coverage, the
country reached universal access levels of 85% in 2012, but with
changing global guidelines, which recommended earlier ART
initiation, the coverage dropped to 53% in December 2013.4
Despite this continued scale-up in numbers of HIV-infected
patients receiving ART, a growing concern in most ART pro-
grammes is patient retention in care, which is critical for the
success of such programmes. A meta-analysis of 32 ART programs
in Africa, excluding Zimbabwe, showed that retention was 60%,
with loss to follow-up being the major cause of attrition, followed
by death.5 Partly associated with attrition from HIV treatment and
care is male gender,6–11 and this has been attributed in part tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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treatment adherence among males.11,13 Despite knowing that
attrition is higher among males, little is known about differences in
the immunological response to ART between males and females in
the routine ART programme setting. Furthermore, few studies have
assessed the factors speciﬁc to males and females that inﬂuence
attrition from ART. Identifying these gender-speciﬁc attrition-
associated factors is critical for determining priority areas for
improving patient retention for each sex.
In Zimbabwe, a review of the national ART programme revealed
that patient retention rates at 36 months was 64.4% and that male
gender increased the risk of attrition.14 Using this dataset we
conducted an extended data analysis aimed at determining: (1)
gender-related differences in ART outcomes, primarily attrition
from treatment, mortality, loss to follow-up, and immunological
failure, and (2) gender-speciﬁc characteristics associated with
attrition.
2. Methods
2.1. Study design
We conducted a retrospective cohort study using routinely
collected ART programme data.
2.2. Setting: general and site-speciﬁc
2.2.1. Clinical procedures in the Zimbabwe National ART Programme
ART eligibility between 2007 and 2009 was based on national
guidelines15 adapted from the World Health Organization
(WHO):16 ART was initiated in patients with a documented HIV-
positive test who were classiﬁed with WHO clinical stage 3 disease
and a CD4+ cell count <350/ml, or WHO clinical stage 4 disease, or
who had a CD4+ cell count <200/ml irrespective of the WHO
staging. Although not mandatory, other recommended psychoso-
cial criteria for evaluating ART eligibility, as they are considered a
measure of patient reliability on treatment, were the following: (1)
compliance with co-trimoxazole prophylaxis using pill counts or
keeping appointments, as this will indicate the likelihood of
adherence to ART; (2) completion of prescribed counselling
session(s); (3) availability of a treatment partner and/or disclosure
to that treatment partner; and (4) ease of follow-up of the patient.
Co-trimoxazole was commenced at least 2 weeks before ART
initiation among adult patients who were either in WHO clinical
stage 2 or higher, or who had a CD4 cell count <200/ml; this would
be continued indeﬁnitely or until the CD4 count was >200/ml for
>6 months.
Women were checked for pregnancy prior to ART initiation as it
was deemed preferable to commence ART after the ﬁrst trimester
so as to minimize the risk of teratogenesis.16 The recommended
ﬁrst-line ART regimen included two nucleoside reverse transcrip-
tase inhibitors (NRTIs), namely stavudine and lamivudine, and one
non-nucleoside reverse transcriptase inhibitor (NNRTI), namely
nevirapine. Zidovudine could replace stavudine in the event of
drug toxicity, while efavirenz could replace nevirapine in the event
of an adverse reaction, during pregnancy, or if a patient was
commenced on tuberculosis (TB) treatment.
2.2.2. Follow-up in the Zimbabwe National ART Programme
Patients are seen every 2 weeks during the ﬁrst month of ART
initiation, then every month for the following 3 months, and are
reviewed every 3 months after the ﬁrst 4 months. Patients can also
visit the clinic immediately if they experience any side effects.
Recommended clinical and laboratory monitoring indices include
the patient’s weight, WHO clinical stage, development of
opportunistic infections (OIs), complete blood count (CBC), serumalanine transaminase (ALT), serum creatinine, and when available
CD4+ cell counts. (Note: CD4 testing was not widely available
between 2007 and 2009. By end of 2009, 68 CD4 machines were in
59 facilities located in 47 out of the country’s 62 districts.17)
Routine clinical monitoring is recommended every 3 months, CBC
and CD4 cell counts should be conducted every 6 months, and ALT
and creatinine should be measured every 12 months. Patient
demographic, clinical, and laboratory information and visit dates
are recorded in the Ministry of Health and Child Care (MOHCC)
medical records maintained at the health facility.
2.2.3. Treatment outcome measures
ART outcomes during data abstraction were categorized as alive
and retained on therapy, died, stopped treatment, transferred out,
defaulted, loss-to-follow-up (LTFU), and other. LTFU was deﬁned as
patient absenteeism from a healthcare facility for >90 days after
the last scheduled appointment with the healthcare provider or
pharmacy, whilst defaulters were those who had not come back to
the clinic for <90 days from the last scheduled appointment. The
LTFU date was recorded as the date of the most recent visit or one
day after ART initiation if patients only attended the initiation visit.
In this analysis, our primary outcomes of interest were clinical ART
outcomes and immunological failure. Clinical outcomes comprised
all-cause mortality, LTFU, and attrition. Attrition referred to
patients who were documented as having stopped ART, died, or
who were LTFU. Immunological failure was deﬁned in line with
WHO 200616 and the Zimbabwe National ART guidelines15 as (1) a
decline in CD4+ cell count after 6 months on therapy, (2) a fall to
pre-therapy CD4 count/percentage, or (3) a CD4 count 100 cells/
ml after at least 6 months on therapy. Overall immunological
failure was then determined as having been classiﬁed with
immunological failure by any of the three criteria stated above.
2.2.4. Study sites
The study was conducted in 40 of 70 health facilities that were
providing ART services to 50 HIV-infected patients for 6 months
by May 31, 2008, for the purposes of logistical and ﬁnancial
feasibility. All provinces countrywide were represented in the
sample whereby sites were selected randomly with the probability
of selection being proportional to the number of adult patients who
had received ART at each site, by May 31, 2008.
2.3. Study participants
Patients were included in the study if they were HIV-infected
and 15 years old and had initiated ART between January 1,
2007 and December 31, 2009. Transfer-in patients were excluded
from the sampling frame in order to avoid double-counting, as they
may have been abstracted as transfer-out at another selected study
site. A minimum of 3842 patients were required for the study,
assuming a design effect of 2, 50% of adult patients were retained
on ART at 12 months after ART initiation, a 95% conﬁdence interval
of 2.5%, and 20% of charts were missing. Patient charts were
selected randomly at each site using an R program.
2.4. Data variables, source of data, and data collection
Data variables included demographic data such as sex and age at
enrolment into HIV care. Clinical information abstracted included
WHO stage, weight, co-trimoxazole use, and CD4 count prior to ART
initiation. Follow-up visit information included weight, haemoglo-
bin, CD4 count, clinical stage, co-trimoxazole prescription, ART
regimen, and the ﬁnal patient outcome. Selected patient ﬁles were
retrieved by ART clinic staff who were responsible for retrieving
selected patient ﬁles, whilst missing ones were replaced by the next
eligible patient record on the randomly ordered list. Trained health
Table 1
Baseline sociodemographic and clinical characteristics of the recruited HIV-positive cohort in the Zimbabwe National ART Programme (2007–2010)
Patient characteristics n N Original dataseta Multiple imputation based data p-Valueb
All patients
(N=3919)
Male
(n=1393)
Female
(n=2514)
All patients
(N=3919)
Male
(n=1393)
Female
(n=2514)
Percentage
(95% CI) or
median (IQR)
Percentage
(95% CI) or
median (IQR)
Percentage
(95% CI) or
median (IQR)
Percentage
(95% CI) or
median (IQR)
Percentage
(95% CI) or
median (IQR)
Percentage
(95% CI) or
median (IQR)
Sociodemographics
Age, years 3733 3733 37 (32–45) 39 (34–48) 36 (31–44) 37 (32–45) 39 (34–48) 36 (31–44) <0.001
Age group, years
15–29 597 3733 16.5% (14.4–18.5) 10.8% (8.3–13.4) 19.5% (17.2–21.8) 16.5% (14.5–18.5) 11.0% (8.6–13.5) 19.6% (17.3–21.8) <0.001
30–39 1548 3733 41.7% (40.0–43.5) 40.1% (37.4–42.8) 42.6% (40.5–44.6) 41.4% (39.6–43.2) 39.8% (37.0–42.5) 42.3% (40.2–44.4)
40–49 991 3733 26.3% (24.8–27.8) 28.8% (26.7–30.8) 25.0% (23.4–26.6) 26.5% (24.9–28.1) 28.9% (26.7–31.1) 25.2% (23.6–26.8)
50 and above 597 3733 15.5% (14.3–16.8) 20.2% (17.5–23.0) 13.0% (12.0–14.0) 15.6% (14.3–16.8) 20.3% (17.5–23.1) 12.9% (11.9–14.0)
Missing 186 3919 4.8% 4.2% 5.0% - - -
Weight, kg 2870 2870 55 (49–61) 56.8 (51–63) 53.7 (47.6–60.0) 55.0 (48.4–61.4) 56.9(47–60) 53.9(47–60) <0.001
Weight category, kg
<45 369 2870 13.1% (10.3–16.0) 8.2% (5.4–11.1) 15.6% (12.3–19.0) 13.3% (10.8–15.8) 8.9% (6.4–11.4) 16.1% (13.2–19.0) <0.001
45–60 1 722 2870 60.4% (57.9–62.3) 54.1% (49.8–58.3) 56.7% (53.7–59.7) 60.0% (57.6–62.3) 53.0% (48.7–57.3) 56.1% (53.3–58.9)
60+ 779 2870 26.5% (22.9–30.1) 37.7% (32.8–42.6) 27.7% (23.6–31.7) 26.8% (23.5–30.0) 38.1% (33.4–42.8) 27.7% (24.2–31.3)
Missing 1049 3919 26.8% 26.6% 26.8% - - -
Clinical characteristics
Days from HIV care
start to ART initiation
2927 2927 29 (2–126) 29 (2–113) 30 (2–131) 36 (1–165) 35 (1–155) 37 (1–173) 0.303
Duration on observed
ART (in months)
3919 3919 16.4 (8.2–27.1) 15.5 (6.4–26.0) 16.8 (9.2–27.6) 16.4 (8.2–27.1) 15.5 (6.4–26.2) 16.8 (9.2–27.6) 0.018
WHO clinical stage
1/2 390 3289 12.4% (6.8–18.1) 11.7% (6.2–17.1) 12.9% (6.8–19.0) 14.4% (8.6–20.1) 11.8% (7.2–16.4) 13.0% (7.9–18.2) 0.1015
3 2413 3289 73.5% (66.9–80.1) 71.9% (65.3–78.6) 74.3% (67.2–81.4) 70.5% (63.9–77.1) 71.9% (66.2–77.6) 74.0% (68.0–80.0)
4 486 3289 14.1% (9.7–18.4) 16.4% (11.6–21.1) 12.8% (8.3–17.3) 15.1% (11.4–19.0) 16.3% (12.2–20.3) 13.0% (9.2–16.8)
Missing 630 3919 16.1% 16.3% 15.8% - - -
Active TBc
Yes 268 2231 12.0% (9.0–15.0) 14.6% (91.8–20.0) 10.4% (8.3–12.6) 10.3% (7.9–12.6) 12.3% (8.4–16.2) 9.1% (7.1–11.2) 0.020
No 1963 2231 88.0% (85.0–91.0) 85.4% (80.0–90.8) 89.6% (87.4–91.7) 89.7% (87.4–92.1) 87.7% (83.8–91.6) 90.9% (88.8–92.9)
Missing 1688 3919 43.1% 42.3% 43.6% - - -
Documented prior TBc
Yes 408 3919 10.3% (5.2–15.3) 12.9% (6.4–19.5) 8.6% (3.9–13.3) 10.3% (6.5–19.5) 13.0% (6.5–19.5) 8.7% (4.0–13.4) 0.005
No 3511 3919 89.7% (84.7–94.8) 87.1% (80.5–93.6) 91.4% (86.7–96.1) 89.7% (84.7–94.8) 87.0% (80.5–93.5) 91.3% (86.6–96.0)
Haemoglobin, g/dl 898 898 10.8 (9.6–12.1) 11.3 (9.9–12.8) 10.7 (9.5–11.8) 10.8 (9.2–12.4) 11.3 (9.7–12.9) 10.6 (9.1–12.1) 0.001
Anaemiad
Yes 695 898 77.4% (74.5–80.0) 76.3% (71.2–80.6) 78.0% (74.4–81.2) 78.6% (76.0–81.2) 80.6% (76.0–85.2) 77.5% (74.1–80.8) 0.023
No 203 898 22.6% (20.0–25.5) 23.7% (19.4–28.8) 22.0% (18.8–25.6) 21.4% (18.8–24.0) 19.4% (14.8–24.0) 22.5% (19.2–25.9)
Missing 3021 3919 77.1% 77.3% 76.9% - - -
CD4 count, cells/ml 1834 3919 121 (55–194) 104 (48–183) 127 (61–199) 121 (55–194) 104 (48–183) 127 (60–199) <0.001
CD4 count category,
cells/ml
<50 401 1834 22.4% (20.2–24.6) 26.3% (23.2–29.4) 19.9% (17.6–22.1) 22.4% (19.8–25.1) 27.0% (23.7–30.3) 20.3% (18.0–22.6) <0.001
50–200 1031 1834 54.9% (51.2–58.7) 55.3% (51.8–58.9) 56.2% (51.3–61.1) 53.4% (49.8–57.1) 54.9% (51.4–58.4) 55.9% (52.6–59.1)
200 402 1834 22.7% (19.5–25.9) 18.3% (16.0–20.6) 24.0% (19.6–28.4) 24.1% (19.6–28.6) 18.1% (15.3–20.9) 23.8% (20.6–27.1)
Missing 2085 3919 53.2% 51.7% 54.1% - - -
Level of healthcare
Primary healthcare
facility
588 3919 15.0% (13.9–16.2) 17.9% (15.9–20.0) 13.4% (12.1–14.8) 9.4% (3.9–14.9) 11.0% (4.6–17.4) 8.6% (3.3–13.8) 0.169
District/mission
hospital
2451 3919 62.5% (61.0–64.0) 59.2% (56.6–61.8) 64.5% (62.6–66.4) 61.5% (36.8–86.2) 59.5% (34.2–84.7) 62.7% (38.2–87.1)
Central/provincial
hospital
880 3919 22.5% (21.2–23.8) 22.9% (20.8–25.2) 22.1% (20.5–23.7) 29.0% (5.0–53.1) 29.0% (4.9–54.1) 28.8% (4.9–52.7)
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ﬁles into paper-based questionnaires, which were eventually
entered into an MS Access database and scanned separately into a
TeleForm database. Differences in the two databases were identiﬁed
using the SAS %COMPARWS Macro.18
2.5. Statistical analysis
Data management was done using SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA), whilst all statistical analyses were performed using
Stata/IC 12.1 (StataCorp, 2011, Stata Statistical Software: Release
12.1; StataCorp LP, College Station, TX, USA). Data were weighted
and the analysis accounted for the complex design of the survey
using the ‘svy’ preﬁx command in Stata. Domain analyses were
performed using the ‘subpop()’ option.
Missing data were assumed ‘missing at random’ (MAR)19 and
were multiple imputed by chained equations using the ‘mi impute
chained’ procedure in Stata. Twenty imputed datasets were
created and estimates were combined according to Rubin’s rules19
using the ‘mi estimate’ procedure. The imputation model included
the Nelson–Aelen estimate of cumulative hazard,20 baseline
demographic and clinical variables, and the event indicator.
Time-to-event data were complete for all individuals. Twenty-
ﬁve patients were LTFU after their ﬁrst clinic visit and were
assigned one day of person-time.
Gender differences in baseline clinical and demographic
characteristics were analysed using linear and logistic regression
models. These analyses were limited to the ﬁrst imputed dataset.
Cox proportional hazards models were used to compare differ-
ences in ART outcomes (mortality, LTFU, and attrition) and
immunological ART outcomes by gender, and also to identify
gender-speciﬁc factors associated with attrition. Multivariable
adjusted hazard ratios (HRs), their 95% conﬁdence intervals (CI),
and p-values were calculated whilst adjusting for the potential
confounding effects of age, baseline weight, baseline CD4 count,
baseline WHO staging, prior/current TB, anaemia, size and location
of OI/ART clinic, and level of health facility. Incidence rates were
also calculated for all clinical ART outcomes and immunological
failure, with the incidence rate being deﬁned as the number of
new cases attaining each outcome in the patient population per
100 person-years (PY) at risk.
For time-to-event analyses, patients who transferred to another
clinic were censored at the date of transfer. However, for
estimating the various immunological ART outcome proportions,
the analysis was restricted to those patients with a baseline CD4
count and at least one CD4 count result 6 months after ART
initiation. Baseline CD4 count was deﬁned as the value on the date
closest to ART start date but not more than 182 days prior to that
date or more than 1 day after that date.
2.6. Ethics and approval
The study protocol was approved by the Medical Research
Council of Zimbabwe (MRCZ) and the Institutional Review Board
(IRB) of the United States Centers for Disease Control and
Prevention prior to data collection. The Union Ethics Advisory
Group also reviewed and approved this extended analysis protocol.
3. Results
3.1. Baseline demographic, clinical, and immunological
characteristics
Data were abstracted from 3919 medical charts of patients
eligible for ART. The level of missing baseline patient data in
these charts varied from <1% (n = 12) for sex, 5% (n = 186) for age,
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(n = 1688) for current active TB, and 53% (n = 2085) for CD4 cell
count to 77% (n = 3031) for haemoglobin levels. Original and
imputed datasets are reported in Table 1, for overall and gender-
speciﬁc baseline demographic and clinical characteristics. The
results of the weighted imputed data are reported below.
At enrolment into HIV treatment, men were older (39
(interquartile range (IQR) 34–48) vs. 36 (IQR 31–44) years; p <
0.001), had higher median baseline weight (57 (IQR 47–60) vs. 54
(IQR 47–60) kg; p < 0.001), and were more likely to have
documented current active TB disease (12% vs. 9%; p = 0.02) and
documented prior TB disease (13% vs. 9%; p = 0.005). Although no
gender differences were noted for the period between enrolment
into HIV care and ART initiation, men were retained on treatment
for fewer months when compared to women (156 (IQR 6–26)
months vs. 17 (IQR 9–28) months; p = 0.018). Similarly the
median baseline CD4 cell count among males was lower when
compared to females (104 cells/ml (IQR 48–183) vs. 127 cells/ml
(IQR 105–181); p < 0.001) and a greater proportion of men
compared to women had a baseline CD4 count <50 cells/ml
(27% vs. 20%, p < 0.001). The prevalence of anaemia was high at
79% of the 23% with recorded baseline haemoglobin levels,
and anaemia prevalence was higher among men than women
(81% vs. 78%; p = 0.023).
3.2. Comparison of patient outcomes by gender
Table 2 shows comparisons of clinical and immunological ART
outcomes by gender. Males had a higher incidence of attrition
(24.0 vs. 19.3 cases/100 PY; p < 0.003), a higher incidence of
mortality (4.7 vs. 2.9 deaths/100 PY; p = 0.003), and a higher LTFU
(4.7 vs. 2.9 cases/100 PY; p = 0.027). Males continued to have a
higher risk of attrition (adjusted hazard ratio (AHR) 1.24, 95%
conﬁdence interval (CI) 1.08–1.43; p = 0.004), mortality (AHR 1.56,Table 2
Comparison of clinical and immunological ART outcomes by gendera
Original Multiple imputation (N
Frequency
(N = 3 919)
All patientsb Males
(n = 1 39
Rate/100 PYd Rate/10
ART outcomes
Attritione 1149 20.9 24.0 
Mortality 221 3.5 4.7 
Loss to follow-up 921 16.9 18.7 
Stopped ART 7 0.1 0.2 
Immunological failure by different deﬁnitions
CD4 count <100 cells/ml after
at least 6 months of initiating therapy
2 199 1.6 1.9 
CD4 count less than pre-therapy
CD4 count at baseline after at least
6 months of initiating therapy
981 2.0 2.5 
50% drop from peak CD4 count value 461 1.7 1.5 
Immunological failure (any deﬁnition)f 1979 0.3 0.3 
ART = antiretroviral therapy; PY = person years; HR = hazard ratio; AHR = adjusted hazar
N = total number of patients with recorded data for each variable.
The bold font was meant to highlight all analysis which had signiﬁcant p-values (i.e. p
a Females are the reference category when interpreting both the univariate and mu
b Take note that sex was missing for 12 patients.
c Hazard ratios have been adjusted for potential confounding effect of age, baseline w
size of OI/ART clinic.
d Rate/100PY is deﬁned as as the number of new cases attaining each outcome in th
e Attrition refers to patients who were documented as having died, stopped ART or wer
after his/her last scheduled appointment with the health care provider or pharmacy).
f Immunologic failure is deﬁned as either CD4<100cells/ml 6 months after initiating th
ART; a 50% drop from the peak CD4 cell count value; or any other deﬁnition of immun95% CI 1.10–2.20; p = 0.014), and LTFU (AHR 1.23, 95% CI 1.05–
1.44; p = 0.012) after adjusting for potential confounding. The
overall incidence of clinical immunological failure was low in this
cohort at 0.3 cases/100 PY and there were no signiﬁcant differences
when stratiﬁed by gender (AHR 1.24, 95% CI 0.25–6.18; p = 0.786)
after adjusting for potential confounders.
3.3. Gender-related differences associated with attrition
Table 3 shows gender-speciﬁc factors associated with attrition.
For males, those with baseline weights of 45–60 kg (AHR 1.37, 95%
CI 1.06–1.76; p = 0.017) and <45 kg (AHR 1.82, 95% CI 1.18–2.81;
p = 0.009) were at increased risk of attrition when compared to
those with baseline weights 60 kg. Among females, only those
with baseline weight <45 kg (AHR 1.92, 95% CI 1.36–2.73;
p = 0.001) were at increased risk of attrition compared to those
60 kg. There was a higher risk of attrition among males with
WHO stage 4 compared to those with WHO stage 1 or 2 (AHR 1.87,
95% CI 1.28–2.73; p = 0.003), whilst no differences were noted
among females. Accessing treatment from urban areas in
comparison to rural areas was associated with a higher risk of
attrition from care for both males (AHR 2.48, 95% CI 1.06–5.81;
p = 0.0037) and females (AHR 3.12, 95% CI 1.29–7.51; p = 0.013).
The baseline CD4 count, current active TB, and prior TB infection
were not signiﬁcant risk factors for attrition in either males or
females after adjusting for confounding. However, attrition was
higher for males accessing ART from district/mission hospitals
(AHR 4.47, 95% CI 1.36–14.67; p = 0.015) or central/provincial
hospitals (AHR 3.52, 95% CI 1.12–11.11; p = 0.033) when compared
to those accessing treatment from primary healthcare facilities. A
similar trend was observed for females receiving treatment from
district/mission hospitals (AHR 7.37, 95% CI 2.32–23.36; p = 0.001)
and central/provincial hospitals (AHR 4.74, 95% CI 1.55–14.53;
p = 0.008). = 3 919)
3)
Females
(n = 2514)
Bivariate Multivariablec
0 PY Rate/100 PY HR (95% CI) p-Value AHR (95% CI) p -Value
19.3 1.22 (1.07–1.39) 0.003 1.24 (1.08–1.43) 0.004
2.9 1.55 (1.23–2.14) 0.009 1.56 (1.10–2.20) 0.014
15.9 1.16 (1.02–1.33) 0.027 1.23 (1.05–1.44) 0.012
0.1 1.34 (0.52–3.51) 0.536 - -
1.4 1.40 (0.95–2.05) 0.084 1.02 (0.67–1.55) 0.925
1.8 1.38 (0.93–2.03) 0.102 1.17 (0.70–1.94) 0.539
1.7 0.89 (0.24–3.34) 0.855 0.85 (0.21–3.42) 0.802
0.2 1.37 (0.27–6.88) 0.694 1.24 (0.25–6.18) 0.786
d ratio; CI = conﬁdence interval; TB = tuberculosis.
 < 0.05).
ltivariate-adjusted hazard ratios.
eight, baseline WHO clinical stage, prior/current TB, anemia, patient residence and
e patient population per 100 person-years at risk.
e lost to follow-up (a patient absent from a healthcare facility for more than 90 days
erapy; CD4 count less than pre-therapy CD4 count,at least 6 months after initiating
ologic failure.
Table 3
Gender-speciﬁc ART attrition in relation to baseline clinical and sociodemographic characteristics among an HIV-positive cohort in the Zimbabwe National ART Programme
(2007–2010)
Patient characteristics
(N = 3919)a
Attritionb
Males (n = 1393) Females (n = 2514)
HR (95% CI) p-Value AHR (95% CI)c p-Value HR (95% CI) p-Value AHR (95% CI)c p-Value
Socio-demographics
Age group, years
15–29 Reference Reference Reference Reference
30–39 0.92 (0.66–1.28) 0.599 0.98 (0.66–1.46) 0.920 0.88 (0.74–1.04) 0.119 0.91 (0.77–1.08) 0.277
40–49 0.78 (0.55–1.12) 0.175 0.86 (0.55–1.34) 0.485 0.71 (0.53–0.96) 0.029 0.72 (0.51–1.02) 0.064
50 and above 0.80 (0.61–1.04) 0.090 0.96 (0.69–1.34) 0.805 0.66 (0.45–0.96) 0.033 0.70 (0.45–1.08) 0.100
Weight category, kg
60+ Reference Reference Reference Reference
45–60 1.39 (1.08–1.79) 0.012 1.37 (1.06–1.76) 0.017 1.20 (0.96–1.50) 0.105 1.15 (0.91–1.46) 0.237
<45 2.06 (1.44–2.94) <0.001 1.82 (1.18–2.81) 0.009 2.02 (1.44–2.83) <0.001 1.92 (1.36–2.73) 0.001
Clinical characteristics
WHO clinical stage, %
1–2 Reference Reference Reference Reference
3 1.47 (0.93–2.34) 0.098 1.29 (0.89–1.88) 0.174 1.12 (0.74–1.70) 0.590 1.05 (0.66–1.67) 0.832
4 1.95 (1.29–2.94) 0.003 1.87 (1.28–2.73) 0.003 1.64 (1.03–2.58) 0.036 1.54 (0.88–2.67) 0.123
Active TB (PTB or EPTB), %
No Reference Reference Reference Reference
Yes 0.71 (0.46–1.10) 0.119 0.80 (0.53–1.23) 0.289 0.91 (0.61–1.35) 0.615 0.95 (0.67–1.34) 0.759
Prior TB (PTB or EPTB), %
No Reference Reference Reference Reference
Yes 0.82 (0.50–1.35) 0.431 0.84 (0.49–1.45) 0.521 0.91 (0.60–1.38) 0.647 0.85 (0.64–1.13) 0.254
CD4 count category, cells/ml
200 Reference Reference Reference Reference
50–200 1.03 (0.70–1.52) 0.870 0.99 (0.70–1.41) 0. 960 1.07 (0.79–1.43) 0.652 0.97 (0.75–1.27) 0.831
<50 1.39 (0.96–2.00) 0.081 1.25 (0.87–1.80) 0.206 1.64 (1.13–2.37) 0.014 1.39 (0.95–2.03) 0.085
Level of healthcare
Primary healthcare facility Reference Reference Reference Reference
District/mission hospital 2.67 (0.89–8.04) 0.078 4.47 (1.36–14.67) 0.015 3.10 (1.29–7.47) 0.013 7.37 (2.32–23.36) 0.001
Central/provincial hospital 3.51 (1.25–9.83) 0.018 3.52 (1.12–11.11) 0.033 3.85 (1.69–8.76) 0.002 4.74 (1.55–14.53) 0.008
Site type
Rural Reference Reference Reference Reference
Urban 1.74 (1.02–2.98) 0.043 2.48 (1.06–5.81) 0.037 1.73 (0.94–3.20) 0.076 3.12 (1.29–7.51) 0.013
OI/ART clinic site sized
50–999 Reference Reference Reference Reference
1000+ 1.70 (0.95–3.02) 0.072 0.87 (0.50–1.52) 0.618 1.51 (0.81–2.81) 0.186 0.81 (0.40–1.67) 0.565
ART, antiretroviral therapy; HR, hazard ratio; CI, conﬁdence interval; AHR, adjusted hazard ratio; WHO, World Health Organization; TB, tuberculosis; OI, opportunistic
infection; PTB, pulmonary TB; EPTB, extrapulmonary TB; N = total number of patients with recorded data for each variable.
The bold font was meant to highlight all analysis which had signiﬁcant p-values (i.e. p < 0.05).
a Sex is missing for 12 patients.
b Attrition refers to patients who were documented as having died, stopped ART, or were lost to follow-up (a patient absent from a healthcare facility for more than 90 days
after his/her last scheduled appointment with the healthcare provider or pharmacy).
c Hazard ratios have been adjusted for potential confounding effects of age, baseline weight, baseline CD4 count, baseline WHO staging, prior/current TB, anaemia, patient
residence, and size of OI/ART clinic.
d OI/ART clinic site size refers to the number of patients enrolled on ART at an opportunistic infections/antiretroviral therapy clinic as at December 31, 2009.
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This study highlights the differences in patient characteristics
as well as treatment outcomes between males and females in a
cohort of HIV-infected patients on ART in the Zimbabwe National
ART Programme. In this study we observed that males had poorer
clinical status prior to initiating ART with regards to current and
previous TB illness when compared to females. Among the few
patients who had haemoglobin measurements taken, anaemia was
more prevalent among males than females, and anaemia has been
shown to be a strong risk factor for disease progression and death
independent of CD4 count and viral load.21,22 Males also had lower
CD4+ cell counts upon initiating ART when compared to females.
These observations indicate that males generally present late for
HIV treatment and care when compared to their female counter-
parts. This is similar to ﬁndings of other studies in both resource-
limited settings7,10,23 and well-resourced settings,24–26 which have
shown that males tend to have more advanced HIV disease upon
initiation of ART. As shown in other studies, such differences in
late ART initiation between males and females can be attributed in
part to clinic-level factors such as the presence of prevention ofmother-to-child transmission of HIV (PMTCT) services at ART
sites27,28 and patient-level factors such as pregnancy and entry
into care through antenatal care (ANC) or PMTCT rather than
through voluntary counselling and testing (VCT).27 This may also
be attributed to a notion of masculinity that portrays men as
resilient and disease-free and hence contradicts expected health-
seeking behaviours such as attending regular hospital visits, as
reported in a local study among rural men.29
Similar to ﬁndings from other studies,12,13,30 males had higher
mortality and attrition from ART care in comparison to females. In
our study, mortality was deﬁned as that which had been
documented in the ART registers and patient ﬁles upon abstraction
of data. Since no efforts were made to follow-up these patients, it is
highly likely that there may have been more deaths among those
who were deﬁned as LTFU in the attrition group, as was reported in
one unpublished study in Zimbabwe (Chigu 2011) and in other
studies from ART programmes in resource-limited settings.31
Among males, factors that were associated with attrition were
lower baseline weight, advanced WHO stage, and accessing
treatment from urban areas. A study done within the South
African ART programme also showed higher mortality among
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the time ART initiation and differences in response to treatment.7
Similar to males, attrition among females was also associated
with lower baseline weight. Low weight is a common problem
among HIV-infected patients even in the era of ART32 and has also
been shown to be a strong independent predictor of mortality.33
Poor nutritional status in HIV-infected patients leads to low
immunity, which predisposes these patients to many severe OIs,
particularly TB. TB is highly prevalent in Sub-Saharan Africa and is
not easily detected clinically; it is therefore likely to manifest in the
early stages of immune reconstitution syndrome. Such TB is better
detected using more sensitive techniques such as the Gene Xpert
MTB/RIF assay,34 which until recently was not available in
Zimbabwe, compared to the conventional acid-fast bacilli smear
microscopy. This could partly explain why only 12% of patients in
this study had active TB at baseline in a setting with high HIV/TB
co-infection.
There are two possible reasons for the higher risk of attrition
among those accessing treatment from urban areas and higher
level health facilities. Firstly, this may be explained by patients
from rural areas or lower level health facilities initiating ART in
urban or higher level health facilities where there was more chance
of ﬁnding doctors; these doctors initiated ART and the patients
then unofﬁcially self-transferred out to rural clinics and lower level
facilities as ART decentralization expanded. These patients may
therefore have been misclassiﬁed as LTFU. In Zimbabwe, ART
initiations were ofﬁcially done only by medical doctors until
recently; however nurses who predominantly run rural and lower
level health facilities have since been empowered to start ART. In
Uganda35 and Malawi,36 a considerable proportion of these LFTU
patients were receiving ART at another facility upon tracing them.
Secondly, higher proportions of patients with advanced disease
may have attended these urban and higher level facilities for
treatment and eventually ART initiation, as they are generally
perceived to offer better health services, whilst more stable
patients may have attended primary care clinics. Such patients
with advanced disease are more likely to die and may have been
masked as LFTU patients. In a systematic review of studies tracing
ART patients lost to follow-up in resource-limited settings,
mortality was shown to range from 20% to as high as 60%.31
In contrast to previous studies,37 the baseline CD4 cell count
was not associated with attrition for both males and females. This
could be explained in part by the amount of missing baseline CD4
count data, which exceeded 50% for the abstracted patient records,
although this missing information was variable among sampled
patient records and did not constitute any speciﬁc subgroup of
patients. Our study did not assess self-reported ART interruptions
or adherence, which may be linked to ART attrition. In a
Cameroonian study by Marcellin et al.,38 pharmacy stock
shortages, binge drinking, and the number of self-reported
slimming symptoms were associated with ART interruptions,
and food supply programs were suggested as interventions to limit
these ART interruptions.
Other study limitations include missing data on haemoglobin
measurements, and given that nearly three-quarters of those with
documented haemoglobin measurements were anaemic, could
suggest that these measurements were taken in those suspected of
having anaemia. Data were also unavailable for patient height and
thus we were unable to calculate body mass index (BMI). Whilst it
may have been ideal to determine actual patient outcomes of all
patients, we could not trace and establish true patient outcomes in
those patients who were classiﬁed as LTFU and there is a possibility
that some may have been alive or dead and thus misclassiﬁed. This
potential misclassiﬁcation of ART patients in the attrition group is
not uncommon in retrospective reviews of other ART patient
cohorts in other resource-limited settings.In conclusion, our study ﬁndings show that males present late
for ART when compared with their female counterparts. This may
partly explain their poorer outcomes in comparison to females.
This observation highlights the need for strategies tailored to
males in order to encourage early HIV testing and enrolment into
HIV treatment and care.
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